111, Inc.
YI · NASDAQ
Company research
111, Inc. (NASDAQ: YI) is a leading tech-enabled healthcare platform company headquartered in Shanghai, China, founded in 2010 by Gang Yu and Junling Liu, and listed on the NASDAQ in September 2018 as the first internet health company from China to do so. The company operates an integrated online-to-offline (O2O) healthcare ecosystem across two core segments — Business-to-Consumer (B2C) and Business-to-Business (B2B) — offering pharmaceutical products, nutritional supplements, medical devices, and personal care items through its platforms 1 Medicine Marketplace, 1 Pharmacy, and internet hospital 1 Clinic. Leveraging its next-generation S2B2C model, 111, Inc. digitally connects patients, pharmacies, pharmaceutical manufacturers, and medical professionals, while providing value-added services such as online consultations, electronic prescriptions, cloud-based inventory management, smart procurement, and omni-channel drug commercialization solutions. With the largest virtual pharmacy network in China serving approximately 580,000 pharmacies nationwide and strategic partnerships with over 500 domestic and international pharmaceutical companies, 111, Inc. remains committed to reshaping the value chain of China's healthcare industry through digital technology and supply chain innovation.
Research reports
Brief news-style research note discussing YI’s intraday price move, emphasizing that analyst consensus remains “Sell” and highlighting weak fundamentals such as negative EPS, low market cap, and thin trading volume, concluding that other stocks are more attractive than YI at current levels.
KoalaGains · November 2, 2025111, Inc. (YI) Fair Value Analysis (2026)In-depth fundamental valuation piece arguing that YI looks significantly undervalued based on extremely low price-to-sales and EV/EBITDA multiples and a very high free cash flow yield, but stressing serious red flags from continued losses and negative shareholder equity, and ultimately framing the stock as a high-risk deep value situation with a fair value range materially above the then-current share price.